Recent findings from the European Medicines Agency have led to a pivotal update in the usage guidelines for the heartburn drug Motilium, also known as domperidone, by the UK's MHRA. The drug now faces restrictions due to links with cardiac complications and fatalities, particularly when misused for non-recommended conditions like heartburn or bloating.